Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serotonin autoreceptor function and antidepressant drug action.

S Hjorth1, H J Bengtsson, A Kullberg

  • 1Institute for Physiology and Pharmacology, Department of Pharmacology, Göteborg University, Sweden. stephan.hjorth@pharm.gu.se

Journal of Psychopharmacology (Oxford, England)
|July 13, 2000
PubMed
Summary

Serotonin (5-HT)1A autoreceptors are key in limiting SSRI effects, with 5-HT1B autoreceptors playing a secondary role. Chronic SSRI treatment still allows autoreceptors to restrain serotonin levels, suggesting potential for adjunctive therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-HER2 treatment in everyday practice: how we treat older women with breast cancer differently.

Breast cancer research and treatment·2026
Same author

A systems biology approach to understand gut microbiota and host metabolism in morbid obesity: design of the BARIA Longitudinal Cohort Study.

Journal of internal medicine·2020
Same author

(3<i>S</i>)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent.

The Journal of pharmacology and experimental therapeutics·2020
Same author

Isotropic model of fractional transport in two-dimensional bounded domains.

Physical review. E, Statistical, nonlinear, and soft matter physics·2013
Same author

The selective 5-hydroxytryptamine 1A antagonist, AZD7371 [3(R)-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide (R,R)-tartrate monohydrate] (robalzotan tartrate monohydrate), inhibits visceral pain-related visceromotor, but not autonomic cardiovascular, responses to colorectal distension in rats.

The Journal of pharmacology and experimental therapeutics·2009
Same author

The orphan receptor GPR55 is a novel cannabinoid receptor.

British journal of pharmacology·2007

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurochemistry

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) are primary treatments for depression.
  • Serotonin (5-HT) autoreceptors, specifically 5-HT1A and 5-HT1B subtypes, modulate serotonin release.
  • Understanding autoreceptor function is crucial for optimizing antidepressant efficacy.

Purpose of the Study:

  • To investigate the relative roles of 5-HT1A and 5-HT1B autoreceptors in SSRI action.
  • To examine autoreceptor responsiveness after chronic SSRI administration.
  • To explore potential for regionally selective modulation of serotonin neurotransmission.

Main Methods:

  • Rat microdialysis studies were conducted.
  • The study reviewed relevant literature on SSRI mechanisms and autoreceptor function.

Related Experiment Videos

Main Results:

  • 5-HT1A autoreceptors are primarily responsible for restraining SSRI-induced serotonin level increases.
  • 5-HT1B autoreceptors have an accessory role in this process.
  • Chronic SSRI treatment does not eliminate autoreceptor function; they continue to limit serotonin transmission.

Conclusions:

  • There is an interplay between cell body and nerve terminal 5-HT autoreceptors.
  • Targeting specific autoreceptor systems may allow for regionally preferential effects on serotonin neurotransmission.
  • Adjunctive treatment with autoreceptor-blocking drugs could benefit patients with partial response to SSRIs.